Loading organizations...
§ Private Profile · Waltham, MA, USA
a life sciences company developing and commercializing molecular diagnostic tests for cardiovascular diseases, focused on heart failure risk.
BG Medicine is a Waltham, Massachusetts-based life sciences company that develops and commercializes biomarker-based molecular diagnostic tests for cardiovascular diseases. The organization's flagship product is the FDA-cleared Galectin-3 blood test, an in vitro diagnostic tool utilized by healthcare providers to assess prognosis and risk in patients with chronic heart failure. The company has collaborated with major diagnostic instrument manufacturers including Abbott, BioMerieux, and Siemens to create automated versions of its tests, while securing backing from investors like Gilde Healthcare and Flagship Pioneering. Before transitioning to over-the-counter trading, the enterprise raised more than $90 million in private venture funding and completed a $40 million initial public offering on the NASDAQ exchange during 2011. The firm currently trades on the OTC markets with 11.37 million shares outstanding. BG Medicine was founded in 2000 by Noubar Afeyan.
BG Medicine has raised $55.0M across 2 funding rounds.
BG Medicine has raised $55.0M in total across 2 funding rounds.
BG Medicine has raised $55.0M across 2 funding rounds. Most recently, it raised $15.0M Debt in March 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2012 | $15M Debt Financing | — | — | Announced |
| Jul 17, 2008 | $40M Series D | — | Stelios Papadopoulos, Noubar Afeyan, GE Asset Management, Humana, Legg Mason Capital Management, SMALLCAP World Fund | Announced |
BG Medicine has raised $55.0M in total across 2 funding rounds.
BG Medicine's investors include Stelios Papadopoulos, Noubar Afeyan, GE Asset Management, Humana, Legg Mason Capital Management, SMALLCAP World Fund.